Jan Astermark
31 – 40 of 188
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
(
- Contribution to journal › Letter
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
International consensus recommendations on the management of people with haemophilia B
(
- Contribution to journal › Scientific review
-
Mark
The journey of gene therapy in haemophilia - Putting the patient at the centre of the hub and spoke model
(
- Contribution to journal › Article
- 2021
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter